Table 1 Patient characteristics and outcome.

From: Ibrutinib for steroid refractory chronic graft-versus-host disease: therapeutic efficiency can be limited by increased risk of fungal infection

Serial/ Gender	Diagnosis	Age (years)	Conditioning regimen/GVHD prophylaxis	Treatment lines before Ibrutinib	Involved organs							Ibrutinib Dose		AE WHO ≥ 3	Response	Steroid dose	Current status
Serial/ Gender	Diagnosis	Age (years)	Conditioning regimen/GVHD prophylaxis	Treatment lines before Ibrutinib	Skin	Eye	Mouth	Lung	GI	Liver	MSK	Initial dose	Last dose	AE WHO ≥ 3	Response	Steroid dose	Current status
P(1)/F	CP1-CML	30	MAC/CSP, MTX	2 lines	x		x			x		140	280	Lung p-IFI Liver toxicity	CR	Off steroid	Alive, in CR off IST
P(2)/M	AML	23	MAC/CSP, MTX	2 lines	x		x	x				280	420	Lung P-IFI skin abscess	CR	Off steroid	Alive, in CR off IST
P(3)/F	AML	54	MAC/CSP, MTX	1 line	x		x	x				280	420	CNS p-IFI Bleeding	PR	75% dose reduction	Died due to CNS fungal infection
P(4)/M	CP2-CML	62	RIC/CSP, MMF	2 lines	x		x	x				280	420	CNS p-IFI Lung p-IFI	PR	35% dose reduction	Died due to CNS fungal infection
P(5)/M	CP2-CML	40	NMA-Haplo/PTCy, Tacrolimus, MMF	2 lines	x	x	x	x	x		x	280	420	Cytopenia Pneumonia Molecular relapse	NR	No reduction	Died due to primary disease relapse
P(6)/F	AML	54	MAC/CSP, MTX	1 line	x		x	x				280	420	Bleeding CNS p-IFI	VGPR	75% dose reduction	Died due to CNS fungal infection
P(7)/M	NHL	22	MAC/CSP, MTX	3 lines	x	x				x		280	140	No AE	VGPR	Off steroid	Alive on low dose Ibrutinib
P(8)/M	AML	46	MAC/CSP, MTX	2 lines	x		x	x		x		280	280	No AE	VGPR	75% dose reduction	Alive on Ibrutinib and low dose steroid
P(9)/M	AML	29	MAC/CSP, MTX	1 line	x	x	x			x		280	420	No AE	PR	50% dose reduction	Alive on Ibrutinib and steroids
P(10)/F	ALL	18	MAC/CSP, MTX	2 lines	x		x			x	x	280	420	No AE	NR	No reduction	Alive, currently on 4^th line treatment for SR-cGvHD
P(11)/M	HL	17	RIC/CSP, MMF	3 lines	x	x			x	x		280	140	no AE	PR	35% dose reduction	Died due to primary disease progression

CR complete remission, VGPR very good partial remission, PR partial remission, NR no response, P patient, M male, F female, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CP1-CML chronic myeloid leukemia in 1st chronic phase, CP2-CML chronic myeloid leukemia in 2nd chronic phase, NHL Non Hodgkin’s lymphoma, HL Hodgkin’s Lymphoma, MAC myeloablative conditioning, RIC reduced intensity conditioning, NMA non-myeloablative conditioning regimen, Haplo haploidentical donor, GVHD graft vs host disease, CSP cyclosporine, MTX methotrexate, MMF mycophenolate mofetil, AE adverse events, p-IFI possible invasive fungal infection, IST immunosuppressive treatment.

Back to article page

Table 1 Patient characteristics and outcome.

Search

Quick links